STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTN
  4. [8-K] PALATIN TECHNOLOGIES INC Reports Material Event

Palatin Technologies (NYSE: PTN) plans move to Nasdaq Capital Market

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Palatin Technologies, Inc. plans to move its common stock listing from the NYSE American to the Nasdaq Capital Market. Trading on the NYSE American is expected to end on May 28, 2026, with Nasdaq trading beginning May 29, 2026, under the same symbol “PTN.”

The company develops melanocortin receptor–targeted therapies, including selective MC4R-based obesity programs for rare disorders such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. A once-weekly injectable MC4R agonist is targeted for an IND submission in the fourth quarter of 2026, and an oral MC4R agonist candidate is targeted for IND submission in the first half of 2027.

Positive

  • None.

Negative

  • None.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice or transferred its listing to a different exchange.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
NYSE trading end date May 28, 2026 Expected last trading day on NYSE American for PTN common stock
Nasdaq trading start date May 29, 2026 Expected first trading day on Nasdaq Capital Market for PTN
Injectable MC4R IND timing Q4 2026 Targeted IND submission for once-weekly injectable MC4R peptide agonist
Oral MC4R IND timing H1 2027 Targeted IND submission for next-generation oral MC4R agonist candidate
Nasdaq Capital Market financial
"its common stock has been approved for listing on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
melanocortin receptor system medical
"novel therapeutics targeting the melanocortin receptor system"
A group of proteins on cell surfaces that act like locks receiving chemical keys to control body processes such as appetite, inflammation, skin pigmentation and energy use. Investors care because drugs that target these receptors can change how those systems work, creating new treatments or markets; progress in research, clinical trials or approvals can therefore drive a company’s value, while failures or safety concerns can harm it.
MC4R-based obesity programs medical
"advancing selective MC4R-based obesity programs targeting rare obesity disorders"
IND submission regulatory
"once-weekly injectable MC4R selective peptide agonist program is on track for an IND submission"
An IND submission is an application a drug developer files with a regulatory authority (for example, the U.S. Food and Drug Administration) asking permission to start testing a new medicine in humans. It shows the company’s lab and safety data and a plan for clinical studies; for investors, an accepted IND is like a green light to move from research to trials, reducing development risk and unlocking value milestones.
forward-looking statements regulatory
"are “forward-looking statements” within the meaning of Section 27A of the Securities Act"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Understanding 8-K Material Events →
false 0000911216 0000911216 2026-05-18 2026-05-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 18, 2026

 

PALATIN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

 

Delaware   001-15543   95-4078884

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

301 Carnegie Center Drive, Suite 304, Princeton, NJ   08540
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (609) 495-2200

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.01 per share   PTN   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On May 18, 2026, Palatin Technologies, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, provided notice to the NYSE American LLC (the “NYSE”) that it intends to voluntarily withdraw the listing of its common stock, par value $0.01 per share (the “common stock”), from the NYSE and transfer the listing of its common stock to the Nasdaq Capital Market (the “Nasdaq”). The Nasdaq has approved such listing. The Company expects the listing and trading of its common stock on the NYSE to cease at the close of trading on May 28, 2026. The Company expects the common stock to begin trading on the Nasdaq on May 29, 2026. The common stock will continue to trade under the symbol “PTN”.

 

Item 7.01. Regulation FD Disclosure.

 

The Company issued a press release on May 18, 2026 announcing the transfer of the listing of its common stock from the NYSE to Nasdaq. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information in Item 7.01, including Exhibit 99.1, of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated May 18, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 18, 2026 PALATIN TECHNOLOGIES, INC.
   
  /s/ Stephen T. Wills
  Stephen T. Wills, CPA, MST
 

Executive Vice President, Chief Financial

Officer and Chief Operating Officer

 

3

 

 

 

Exhibit 99.1

 

Palatin to Begin Trading on Nasdaq Stock Exchange

 

PRINCETON, NJ – May 18, 2026 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.

 

The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol “PTN.” Palatin’s common stock will continue to trade on the NYSE American until the market close on May 28, 2026.

 

“We are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotechnology companies,” said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. “We believe the move to Nasdaq will improve the visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.”

 

Palatin is advancing selective MC4R-based obesity programs targeting rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with a focus on improved tolerability and long-term use. The Company’s once-weekly injectable MC4R selective peptide agonist program is on track for an IND submission in the fourth quarter of calendar 2026, and its oral MC4R selective agonist program continues to advance, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027. Palatin’s development strategy is focused on advancing potential best-in-class MC4R candidates designed to enhance potency, improve tolerability, reduce off-target effects, including those associated with hyperpigmentation, and support safe and effective long-term use.

 

No action is required by existing stockholders with respect to the transfer of the Company’s listing.

 

About Palatin

 

Palatin is a biopharmaceutical company developing medicines that target the melanocortin receptor system with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form collaborations with industry leaders to maximize their commercial potential. For more information, visit the company’s website at www.palatin.com and follow us on X, formerly Twitter, @PalatinTech.

 

-More-

 

 
 

 

Forward-looking Statements

 

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about the commencement of trading of Palatin’s common stock on the Nasdaq Capital Market. Palatin products in development, clinical trial results, potential actions by regulatory agencies, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin’s ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin’s products, and other factors discussed in Palatin’s periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.

 

Investor Inquiries:   Media Inquiries:
     
Stephen T. Wills, CPA, MST   Paul Arndt, MBA, LifeSci Advisors, LLC
Chief Financial Officer/Chief Operating Officer   Managing Director
Tel: (609) 495-2200 / Info@palatin.com   Tel: (646) 597-6992 / Paul@LifeSciAdvisors.com

 

Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.

 

###

 

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What stock exchange change did Palatin Technologies (PTN) announce?

Palatin Technologies plans to transfer its common stock listing from the NYSE American to the Nasdaq Capital Market. Trading is expected to end on NYSE American May 28, 2026, and begin on Nasdaq May 29, 2026, with the ticker symbol remaining “PTN.”

When will Palatin Technologies (PTN) begin trading on Nasdaq?

Palatin expects its common stock to begin trading on the Nasdaq Capital Market on May 29, 2026. Shares will trade on the NYSE American until market close on May 28, 2026, and the company will keep its existing ticker symbol “PTN.”

What is Palatin Technologies’ core therapeutic focus?

Palatin develops medicines targeting the melanocortin receptor system. Its programs include selective MC4R-based obesity treatments for hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, aiming for improved tolerability, reduced off-target effects, and safe long-term use in diseases with significant unmet medical need.

What are the key milestones for Palatin’s MC4R obesity programs?

Palatin’s once-weekly injectable MC4R selective peptide agonist program is on track for an IND submission in the fourth quarter of 2026. Its next-generation oral MC4R selective agonist candidate is targeted for IND submission in the first half of 2027, subject to development progress.

Will Palatin Technologies stockholders need to take action for the Nasdaq transfer?

Existing stockholders are not required to take any action regarding the exchange transfer. The company states that no action is required as the common stock will simply move from trading on the NYSE American to the Nasdaq Capital Market while retaining the symbol “PTN.”

How does Palatin describe potential benefits of moving to Nasdaq?

Palatin’s CEO states the company believes a Nasdaq listing will improve the visibility of its common stock, enhance trading liquidity, and provide greater exposure to institutional investors. These points are presented as expectations and beliefs, consistent with the forward-looking nature of the company’s statements.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents